Shares of Bio-Techne TECH were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share were up 87.00% over the past year to $1.87, which beat the estimate of $1.70.
Revenue of $259,028,000 rose by 47.31% year over year, which beat the estimate of $244,620,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 05, 2021
Time: 09:00 AM
ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1481160&tp_key=8a365aa878
Recent Stock Performance
52-week high: $488.23
52-week low: $228.66
Price action over last quarter: Up 15.06%
Company Profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.